

**Date:** October 09, 2025

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

Dear Sir/Madam,

**Sub: Submission of Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2025 under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.**

In compliance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed herewith Reconciliation of Share Capital Audit Report, dated October 08, 2025 duly signed and issued by Mr. Tapan Shah, Company Secretary in Practice, for the quarter ended on September 30, 2025.

Kindly take the same on your records.

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

Encl.: As mentioned above

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

To,  
 The Board of Directors,  
**SENORES PHARMACEUTICALS LIMITED,**  
 1101 to 1103, 11<sup>th</sup> floor, South Tower, ONE 42,  
 Opp. Jayantilal Park, Ambali Bopal Road,  
 Ahmedabad, Gujarat, India, 380054

### RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

CIN : L24290GJ2017PLC100263  
 Authorised Capital : Rs. 59,00,00,000

I have examined the Register of Members, beneficiary details given by the Depositories and other records / documents maintained by **M/s. SENORES PHARMACEUTICALS LIMITED**, having its Registered Office at 1101 to 1103, 11<sup>th</sup> floor, South Tower, ONE 42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054 for issuing Certificate, in accordance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 read with Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 issued by the Securities and Exchange Board of India (SEBI). To the best of my knowledge and according to the information and explanation given to me and as per the record received through mail and examined by me, I hereby certify that for the quarter ended September 30, 2025, the details of position of Company's Capital Structure, its Equity shares position with NSDL, CDSL and in Physical form, the Demat activity carried out and any pending Demat status and other details are as under:

1	For Quarter Ended	30/09/2025
2	ISIN	INEORB801010
3	Face Value	Rs. 10/- per Share
4	Name of the Company	<b>SENORES PHARMACEUTICALS LIMITED</b>
5	Registered Office Address	1101 to 1103, 11 <sup>th</sup> floor, South Tower, ONE 42 Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad, Ahmedabad, Gujarat, India, 380054.
6	Correspondence Address	-- Same as above --
7	Telephone & Fax Nos.	Tel. 079- 29999857
8	Email Address	cs@senorespharma.com
9	Name of the Stock Exchanges where the Company's Securities are listed with scrip code	1. National Stock Exchange of India Limited. (Symbol: SENORES) 2. BSE Limited (Scrip Code: 544319)
10	Issued Equity Share Capital	No. of Shares 4,60,53,588



11	Listed Equity Capital (as per company records)		4,60,53,588				
			<b>No. of shares</b>		<b>% of issued Capital</b>		
12	Held in dematerialized form in NSDL		2,78,59,631		60.49		
13	Held in dematerialized form in CDSL		1,81,93,957		39.51		
14	Physical		0		0.00		
15	Total No. of Shares (12+13+14)		4,60,53,588		100.00		
16	Reason for difference, if any, between (10&11), (11 & 15)		N.A.				
17	Certifying details of changes in share capital during the quarter under consideration as per Table below :						
Particulars	No. of Shares	Applied/ not Applied for Listing	Listed on Stock Exchanges (Specify Names)	Whether intimate d to CDSL	Whether intimate d to NSDL	In-principle Approval Pending for SE (Specify Names)	
NA	NA	NA	NA	NA	NA	NA	
18	Register of Members is updated (YES/NO) if not, updated up to which date			Yes			
19	Reference of previous quarter with regards to excess dematerialized shares, if any			-- N.A. --			
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?			-- N.A. --			
21	Mentioned the total no. of requests, confirmed after 21 days and the total no. of requests pending beyond 21 days (in both cases, from the date of DRN & confirmed by the Registrar is taken), with the reasons for delay:						
Total No. of demat requests			No. of requests		No. of shares		Reasons for delay
			NSDL	CDSL	NSDL	CDSL	
Confirmed after 21 days			--	--	--	--	N.A.
Pending for more than 21 Days			--	--	--	--	
22	Name, Telephone & Fax No. of Compliance Officer of the Co.			Mr. Vinay Kumar Mishra, Company Secretary and Compliance Officer. Tel.: +91-79-29999857 E-mail: <a href="mailto:cs@senorespharma.com">cs@senorespharma.com</a>			

23	Name, Address, Tel. & Fax No. of the Company Secretary in whole-time practice	Mr. Tapan Shah (CP No.2839) 816-818, Anand Mangal-3, Nr. Doctor House, Ellisbridge, Ahmedabad-6 Tel.: 40024320 E-Mail: <a href="mailto:info@tapanshah.in">info@tapanshah.in</a>
24	Appointment of Common Agency for Share Registry Work (Name & Address)	MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) C 101, Embassy 247, L.B, S. Marg, Vikhroli (West), Mumbai- 400083, Maharashtra, India. Tel-022-49186270/ 49186000, Fax-022-49186060, E-mail: <a href="mailto:investor.helpdesk@in.mpms.mufig.com">investor.helpdesk@in.mpms.mufig.com</a>
25	Any other detail that the Co. Secretary may like to provide (e.g. BIFR Co., delisting from SE, Company changed its name etc.)	<ul style="list-style-type: none"> <li>During the quarter, in AGM held on September 18, 2025, members approved the revision in remuneration of Mr. Swapnil Jatinbhai Shah (DIN: 05259821), Managing Director of the Company and Mr. Chetan Bipinchandra Shah (DIN: 10381971), Whole-Time Director and Chief Operating Officer (COO) of the Company.</li> </ul>

Place: Ahmedabad  
Date: 08/10/2025

Signature: TAPAN RAJNIKANT SHAH  
 Digitally signed by TAPAN RAJNIKANT SHAH  
 Date: 2025.10.08 10:54:28 +05'30'  
 Name of Company Secretary: TAPAN SHAH  
 C. P. Number: 2839  
 UDIN: F004476G001486649

**Note:**

Above report was prepared based on the softcopy of the papers/ report/ documents provided by the Share Registry of the Company, i.e. MUFG Intime India Private Limited. (Formerly known as Link Intime India Private Limited)

